Table 3. Adjusted Treatment Persistence and Risk of Discontinuation Among All Patients (N=265)^a.

	Persistence at 12 Months: OR (95% CI)	P-Value	Risk of All-Cause Discontinuation: HR (95% CI)	P-Value	Risk of Discontinuation for Disease Progression	P-Value
Clinic
1 vs. 6	3.208 (0.839 - 12.275)	0.089	0.459 (0.214 - 0.985)	0.046	0.472 (0.144 - 1.547)	0.215
2 vs. 6	1.679 (0.522 - 5.396)	0.385	0.481 (0.242 - 0.957)	0.037	0.484 (0.163 - 1.436)	0.191
3 vs. 6	14.754 (3.440 - 63.274)	<0.001	0.286 (0.144 - 0.569)	<0.001	0.192 (0.060 - 0.615)	0.006
4 vs. 6	3.656 (1.076 - 12.425)	0.038	0.299 (0.146 - 0.614)	0.001	0.016 (0.002 - 0.150)	<0.001
5 vs. 6	1.762 (0.397 - 7.809)	0.456	0.562 (0.236 - 1.339)	0.194	0.930 (0.273 - 3.167)	0.908
Male vs. Female	0.508 (0.255 - 1.010)	0.053	1.216 (0.826 - 1.791)	0.321	1.280 (0.688 - 2.380)	0.435
Age, Years	1.013 (0.988 - 1.039)	0.319	1.002 (0.988 - 1.016)	0.803	0.996 (0.973 - 1.019)	0.711
CCI	1.003 (0.731 - 1.377)	0.985	1.012 (0.842 - 1.216)	0.898	0.982 (0.730 - 1.321)	0.903
Years from RA Diagnosis	0.988 (0.951 - 1.027)	0.540	1.010 (0.987 - 1.033)	0.408	1.018 (0.981 - 1.056)	0.341
No. Physician Office Visits (1-year pre-index)	Not significant		Not significant		Not significant
No. Hospitalizations (1-year pre-index)	Not significant		Not significant		Not significant
Abatacept vs TNFi	1.980 (0.943 - 4.167)	0.071	0.584 (0.384 - 0.887)	0.012	0.293 (0.138 - 0.620)	0.001

Abbreviations: CCI, Charlson comorbidity index; CI, confidence interval; HR, hazard ratio; OR, odds ratio; RA, rheumatoid arthritis; TNFi, tumor necrosis factor inhibitor.

^a The initial models included age, sex, CCI, years from RA diagnosis to index, and cohort as independent variables. We then used a forward selection method to include additional significant covariates (P<0.05) for the final models. The following covariates were considered: number of physician office visits (1-year pre-index), number of hospitalizations (1-year pre-index), and site.